Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study

Affiliation auteurs!!!! Error affiliation !!!!
TitreEfficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study
Type de publicationJournal Article
Year of Publication2018
AuteursJackisch C, Stroyakovskiy D, Pivot X, Ahn J-S, Melichar B, Chen S-C, Meyenberg C, Al-Sakaff N, Heinzmann D, Hegg R
JournalCANCER RESEARCH
Volume78
Date PublishedFEB
Type of ArticleMeeting Abstract
ISSN0008-5472